Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL28923637 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL503658 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL15670767 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL17337984 | 0.98 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL11670059 | 0.98 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL11670058 | 0.98 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL11670811 | 0.96 | SLC7A5 (0.40) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL29915024 | 0.96 | SLC7A5 (0.40) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL11670808 | 0.96 | SLC7A5 (0.40) | SLC7A5CYP3A4CYP1A2PTPRCALPI | |
| Histidine SCHEMBL11670599 | 0.94 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2PTPRCALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 942 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119979580-A | Method for producing 1, 3-dihydroxyacetone | 中国科学院天津工业生物技术研究所 | 2025-05-13 | — | — | CN | claimed |
| US-12030948-B2 | Antibody formulation | DR. REDDY'S LABORATORIES LIMITED (IN) | 2024-07-09 | — | — | US | claimed |
| CN-117942300-A | Liquid formulations comprising anti-IL-17 antibodies | 甘李药业股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| US-20240100158-A1 | FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2024-03-28 | — | — | US | claimed |
| US-20240084016-A1 | STABLE FORMULATION OF INTEGRIN ANTIBODY | DR. REDDY'S LABORATORIES LIMITED (IN) | 2024-03-14 | — | — | US | claimed |
| CN-112430560-B | 2-keto-L-gulonic acid production strain and construction method thereof | 中国科学院分子植物科学卓越创新中心 | 2024-01-05 | — | — | CN | claimed |
| EP-4281045-A1 | FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF | Dr. Reddy's Laboratories Limited (IN) | 2023-11-29 | — | — | EP | claimed |
| EP-4243859-A1 | STABLE AQUEOUS HIGH CONCENTRATION FORMULATION OF INTEGRIN ANTIBODY | Dr. Reddy's Laboratories Ltd. (IN) | 2023-09-20 | — | — | EP | claimed |
| WO-2016109822-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NOVELMED THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | claimed |
| EP-2373294-B1 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS | ALLERGAN INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-20130137639-A1 | STABLE MIA/CD-RAP FORMULATION | SCIL TECHNOLOGY GMBH (DE) | 2013-05-30 | — | — | US | claimed |
| EP-2563809-A2 | STABLE AQUEOUS MIA/CD-RAP FORMULATIONS | Scil Technology GmbH (DE) | 2013-03-06 | — | — | EP | claimed |
| WO-2011134979-A9 | STABLE AQUEOUS MIA/CD-RAP FORMULATIONS | SCIL TECHNOLOGY GMBH (DE) | 2012-08-16 | — | — | WO | claimed |
| CN-102307571-A | Clostridial toxin pharmaceutical compositions | ALLERGAN INC | 2012-01-04 | — | — | CN | claimed |
| WO-2011134979-A2 | STABLE MIA/CD-RAP FORMULATION | SCIL TECHNOLOGY GMBH (DE) | 2011-11-03 | — | — | WO | claimed |
| EP-2373294-A1 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS | Allergan, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010090677-A1 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS | ALLERGAN, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| CN-1709262-A | Injection cefteram composition | HUANG WENHAO (CN) | 2005-12-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | SLC7A5 157/4885CYP3A4 4877/4885CYP1A2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.